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ABSTRACT 17 
The aim of this investigation is to study the effect of donor concentration and microneedle 18 
(MN) length on permeation of insulin and further evaluating the data using scaling analyses 19 
and numerical simulations. Histological evaluation of skin sections was carried to evaluate 20 
the skin disruption and depth of penetration by MNs. Scaling analyses was done using 21 
dimensionless parameters like concentration of drug (Ct/Cs), thickness (h/L) and surface area 22 
of the skin (Sa/L2). Simulation studies were carried out using MATLAB and COMSOL 23 
software to simulate the insulin permeation using histological sections of MN treated skin 24 
and experimental parameters like passive diffusion coefficient. A 1.6 fold increase in 25 
transdermal flux and 1.9 fold decrease in lag time values were observed with 1.5mm MN 26 
when compared with passive studies. Good correlation (R2>0.99) was observed between 27 
different parameters using scaling analyses. Also, the in vitro and simulated permeations 28 
profiles were found to be similar (f2≥50). Insulin permeation significantly increased with 29 
increase in donor concentration and MN length (p<0.05). The developed scaling correlations 30 
and numerical simulations were found to be accurate and would help researchers to predict 31 
the permeation of insulin with new dimensions of MN in optimizing insulin delivery.  32 
2 
 
Overall, it can be inferred that the application of MNs can significantly enhance insulin 33 
permeation and may be an efficient alternative for injectable insulin therapy in humans. 34 
 35 
KEY WORDS: Histological studies, Insulin skin permeation, Microneedle arrays, Numerical 36 
simulations, Scaling analyses. 37 
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INTRODUCTION 39 
Diabetes mellitus is a metabolic disorder, which is characterized by insufficient production of 40 
insulin (type I) or failure of the body to utilize the insulin produced (type II).  Currently the 41 
number of patients suffering from diabetes mellitus is about 285 million adults worldwide, 42 
and by the year 2030 the numbers are expected to reach 439 million adults (1). Insulin, a 43 
pancreatic peptide hormone, is used in the treatment of insulin dependent diabetes mellitus 44 
(IDDM or type-I DM). Insulin is a water soluble, unstable protein with a molecular size more 45 
than 5000kDa. 46 
Insulin cannot be administered orally as it is severely degraded in GIT by the process of 47 
digestion (2). Drug delivery via the parenteral route, either by subcutaneous or intramuscular 48 
injection, is particularly common. Injection by hypodermic needle has been ‘the gold 49 
standard’ for insulin delivery for over a century (3). However, administration of insulin by 50 
hypodermic needles often causes pain, peripheral hyperinsulinemia, smooth muscle cell 51 
proliferation and a diabetic micro- and macro-angiopathy and may transmit pathogens 52 
through needle re-use and require medical expertise(4, 5). In addition, the burden of daily 53 
injections, patient non-compliance, physiological stress, inconvenience, cost, and the 54 
localized deposition of insulin leads to a local hypertrophy and fat deposition in the injection 55 
sites. To alleviate these drawbacks, transdermal route for insulin delivery can be used as an 56 
alternative non-parenteral route of administration to treat insulin dependent diabetic patients. 57 
Given the very low diffusivity of insulin in stratum corneum owing to its high molecular 58 
weight and its hydrophilic nature, an efficient permeation enhancement technique must be 59 
employed to enhance the transdermal permeation of insulin.  60 
Literature review revealed that a number of works have been reported on the transdermal 61 
delivery of insulin. Some of the works utilized various permeation enhancers alone and along 62 
with iontophoresis for insulin permeation enhancement (6, 7). Some works were also carried 63 
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out using microneedles (MN) to enhance the transdermal delivery of insulin (8-12). While 64 
these works show the potential of using MN for enhancement of insulin delivery, and no 65 
works depicting a systematic approach to evaluate the overall dependence of insulin 66 
permeation on various parameters, for example, the MN lengths (MN density in a patch) and 67 
insulin donor concentration, etc. have been explored in detail. 68 
In addressing this issue, we have carried out a series of well-defined in vitro experiments for 69 
the evaluation of insulin transdermal permeation using (i) insulin solutions of two different 70 
strengths and volumes as donor vehicle, (ii) the effect and relative efficacy of different 71 
lengths of MN on insulin permeation enhancement. Moreover, the obtained data was 72 
subjected to mathematical treatment using scaling analyses to obtain correlations 73 
between dimensionless amount of insulin permeated (Ct/Cs) and various variables of the 74 
study like surface area (Sa/L2) and thickness (h/L) of skin based on the Buckingham π 75 
theorem (13).  Numerical simulations of the in vitro experiments using histological 76 
section images and passive diffusion coefficient values were also carried out in order to 77 
simulate the insulin permeation process under realistic conditions and gain insights into 78 
the phenomenon of insulin transport behaviour and insulin distribution in the MN 79 
treated skin (14). Commercially available MN arrays (AdminPatch®) with four different 80 
needle lengths (0.6, 0.9, 1.2 and 1.5 mm) and MN density were utilized for the purpose of 81 
this study. Also, a new RP-HPLC-PDA method was developed for the insulin analysis. 82 
MATERIALS AND EXPERIMENTAL METHODS 83 
Materials 84 
The materials used for this research work include Insugen-R (Biocon, Bangalore, India), high 85 
performance liquid chromatography (HPLC) grade acetonitrile, water and  formic acid (E. 86 
Merck, Mumbai, India), sodium chloride, isopropyl alcohol (S.D. Fine chem. Ltd, Mumbai, 87 
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India), and haematoxylin and eosin (Sigma-Aldrich, Dorset, UK). AdminPatch® arrays (0.6, 88 
0.9, 1.2 and 1.5 mm MN lengths) were purchased from Admin Med (Sunnyvale, CA, USA). 89 
The pig ears were obtained from a local slaughter house. 90 
Methods 91 
Analytical method 92 
The insulin analysis was performed on a Shimadzu chromatographic system equipped with 93 
HPLC Shimadzu pump LC-20AD, SIL-20A auto sampler with 200µL loop volume, 94 
programmable variable wavelength PDA detector SPD-M20A VP, and Inertsil C18 column 95 
(250×4.6 mm, 5 µm). The HPLC system was equipped with LC-solution software to acquire 96 
and process the data. The mobile phase consisted of 0.02% v/v formic acid and acetonitrile 97 
(40:60 v/v) and pumped at a flow rate of 1.0 mL/min.  The eluents were monitored at a 98 
wavelength of 215 nm at ambient temperature with an injection volume of 20µL. An 99 
appropriate volume of the insulin stock solution was diluted with 0.9% w/v sodium chloride 100 
to get the required standard solutions at a concentration range of 5-40µg/mL. The proposed 101 
method was validated as per ICH guidelines (15). 102 
Preparation of 0.9% (w/v) sodium chloride solution 103 
0.9g of sodium chloride was accurately weighed and transferred to a clean and dry 100mL 104 
volumetric flask containing 50mL of HPLC water and dissolved. The volume was made up to 105 
mark to get 0.9% (w/v) sodium chloride solution. 106 
Determination of insulin stability 107 
The stability of insulin in saline solution was studied over a period of 48 h by storing 1mL 108 
aliquots of 30µg/mL insulin in centrifuge tubes at a temperature of 37ºC.  Samples were 109 
6 
 
withdrawn at different time intervals for 48 h and analysed for insulin content by RP-HPLC-110 
PDA method. 111 
Skin preparation 112 
The ears were collected from the local abattoirs (pigs aged about 6-7 months) and the ears 113 
were transported to the laboratory in a cooling box without previous treatment. Freezing of 114 
the skin was avoided during transport. In the laboratory, the pig ears were washed carefully 115 
with water. The hair was removed from the external part of pig ear using an electrical hair 116 
clipper. Then, the full-thickness skin was separated from the external part of the pig ear using 117 
a scalpel and excess fat under the skin was removed to a thickness of 1.2 mm for all the skin 118 
samples. Dermis side was wiped with isopropyl alcohol to remove residual adhering fat. The 119 
pieces of skin obtained were individually wrapped in plastic bags and stored in a deep freezer 120 
at -20°C till further use. 121 
MN treatment of pig ear skin 122 
Prior to the permeation experiments, the frozen skin samples were brought to room 123 
temperature and then the skin pieces were carefully washed with saline solution in a 124 
petridish. The MN arrays differing in their needle lengths (0.6mm, 0.9mm, 1.2mm and 125 
1.5mm) were pressed over the skin pieces at a constant thumb pressure. Photographs of the 126 
MN arrays with different needle lengths were shown in Fig. 1. The MNs were periodically 127 
checked in between usage for potential damages of the needle under a stereo microscope. 128 
Histological examination and calculation of penetration depth 129 
The histological sections of the skin samples without and with MN treatment were observed 130 
under the PZRM-700 microscope (Quasmo, Haryana, India). Skin samples were stained with 131 
hematoxylin and eosin (H&E) stains for visualization of skin layers and to display a clear 132 
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indentation of the MN penetration. The depth of MN penetration into skin was also calculated 133 
with the help of ToupView 3.2 Software (AmScope, Irwin, USA). 134 
In vitro permeation studies 135 
Franz diffusion cell apparatus (Orchid Scientifics, Nasik, India) consisting of a water 136 
circulation system, a water heater and an eight stage magnetic stirrer was used to carry out 137 
permeation studies. The diffusion cells (1.77 cm2 diffusional area and a receptor volume of 138 
14mL) were employed for conducting the permeability studies and the donor compartment 139 
was charged with insulin solutions (i.e., 40 and 100 IU/mL at 0.5 and 1mL donor volumes) 140 
while the receiving compartment was loaded with  saline solution. 141 
Pig ear skin was mounted between donor and receptor compartments, with the stratum 142 
corneum side facing towards the donor compartment and clamped. The receptor medium was 143 
magnetically stirred at a speed of 600 rpm for uniform distribution of insulin. Care was taken 144 
to prevent possible entrapment of air bubbles under the skin (dermis) and in receptor solution. 145 
The surface of the skin was maintained at 32°C using a circulating water bath. After 146 
equilibration, insulin solution was charged on to the skin. At predetermined time points, 0.5 147 
mL samples were withdrawn from the receptor fluid and replaced with fresh medium 148 
immediately. The amount of insulin in samples was analysed by RP-HPLC-PDA method. 149 
The insulin skin permeation profiles were plotted for passive and MN (0.6, 0.9, 1.2 and 1.5 150 
mm) treated skin permeation studies. The flux values and respective lag time values were 151 
obtained from the slope and X-intercept of the steady state portion of the permeation profiles. 152 
Insulin content in skin 153 
Insulin retained within the skin was measured at the end of the experiment. The skin tissue 154 
exposed to the donor solution was cut with a scalpel and rinsed with water and blotted with a 155 
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paper towel in order to remove the adhered insulin to the surface. The skin was then minced 156 
with a scalpel, and placed in a pre-weighed vial. The insulin was extracted from the skin by 157 
equilibrating with 1mL of acetonitrile at room temperature on an orbital shaker (60 rpm). 158 
Samples were analysed by HPLC to determine the insulin content. 159 
Scaling Analyses 160 
Scaling analyses were performed using amount of insulin permeated (Ct/Cs) and other 161 
variables of the study like surface area (Sa/L2) and thickness (h/L) of skin using the 162 
Buckingham π theorem where it is defined that the dimensionless concentration of a drug, 163 
which permeates through skin sample, can be defined in terms of key non-dimensional 164 
parameters, e.g., MN lengths (13).  Full details of the approach for the non-dimension 165 
analyses have been discussed earlier (13), and therefore they are not discussed in this paper.  166 
Eq. 1 describes the relationship of all the parameters used for such analyses and the various 167 
method parameters used in this study for scaling analyses are given in Table I. 168 
Ct
Cs
= K �SaL4Ke
VdhD
�
n
 ---- (1) 169 
Where, K is a dimensionless constant and n is an unknown power; Ct and Cs are the amount 170 
of drug permeated at a given time t (6 h) and the amount of drug loaded for diffusion (surface 171 
concentration on skin); Sa is the surface area of the patch or MN treated area of the skin; L is 172 
the length of MN; Ke is the first order elimination constant of drug; Vd is the volume of 173 
receptor fluids (in vitro); h is the thickness of skin and D is the diffusion coefficient of insulin 174 
in skin. Using Eq. 1, the correlations between the groups referring to the dimensionless 175 
insulin concentration (Ct/Cs) against different dimensionless parameters of study, h/L and 176 
Sa/L2, have been established considering that all other variables remain unchanged. 177 
  178 
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Numerical Simulation of Permeation Experiments 179 
Simulations were carried out using a MATLAB (Math Works, MA, USA) program, which 180 
was employed to prepare the microphotographs of histological sections of skin treated with 181 
MN.  These images, coupled with the experimental parameters, e.g., passive diffusion 182 
coefficient obtained from the in vitro studies were imported into a simulator software, 183 
COMSOL Multiphysics (COMSOL Multiphysics Pvt. Ltd., Stockholm, Sweden), in order to 184 
simulate the insulin transport behaviour across skin and predict the permeation profiles of 185 
insulin as per the procedures reported by Han and Das (14). 186 
Statistical analysis of the data 187 
Statistical analysis of the data and different parameters obtained with skin permeation 188 
experiments were computed with a one-way ANOVA analysis (Fischer’s LSD post hoc test) 189 
using SYSTAT 13 software (Systat Software Inc., CA, USA). Results with p-value less than 190 
0.05 were considered to be statistically significant variance. 191 
RESULTS  192 
Analytical method 193 
In the present investigation, a rapid, efficient RP-HPLC-PDA method was developed for the 194 
quantitative estimation of insulin. The method was validated according to the ICH guidelines 195 
and it complies with all specifications (15). The validation data was given in Table II. Insulin 196 
eluted at 6.08 min, which showed a good linearity in the concentration range of 5-40 µg/mL 197 
with a correlation coefficient of 0.999. The percent recoveries ranged between 98 and 102 198 
(RSD < 2).  199 
  200 
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Determination of insulin stability 201 
Stability of insulin in 0.9%w/v saline solution, over a period of 48 h was studied and the data 202 
revealed that the % variation in insulin content at different time intervals was found to be less 203 
than 2%. The results of the stability studies showed good insulin stability over the entire 204 
experimental duration with no significant degradation. 205 
Histological examination and calculation of penetration depth 206 
Histological sections were prepared using haematoxylin and eosin stain and representative 207 
microscopic images were shown in Fig. 4 (A). The photographs clearly indicated the stratum 208 
corneum barrier disruption and the formation of microconduits across the skin layers. The 209 
representative penetration depth values for the MNs used were calculated using ToupView® 210 
software and were found to be approximately 363.25, 521.16 and 642.34 µm for 0.6, 1.2 and 211 
1.5 mm MN lengths.  212 
 213 
In vitro permeation studies 214 
Passive in vitro permeation studies were carried out using 40 and 100 IU/mL strength insulin 215 
solutions at 0.5 and 1.0 mL donor volumes. The amount of insulin permeated through skin at 216 
different time intervals was determined by the RP-HPLC-PDA method. The cumulative 217 
amounts of insulin permeated through intact pig ear skin at the end of 6 h were found to be 218 
329.66 ± 23.78 and 355.93 ± 21.17 µg/cm2 respectively for 0.5mL and 444.19 ± 19.53 and 219 
452.84 ±27.57µg/cm2 respectively for 1mL of 40 and 100 IU/mL insulin solutions. On the 220 
other hand, the steady state flux values were found to be 71.66 ± 3.72 and 76.95 ± 3.86 221 
µg/cm²/h for 0.5mL donor volume and 91.05 ± 6.66 and 92.12 ± 6.75 µg/cm²/h for 1mL 222 
donor volume respectively for 40 and 100 IU/mL strength insulin solutions. Hence, for 223 
further MN treated studies, 1 mL of 100 IU/mL strength insulin solution was used as donor 224 
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vehicle. The cumulative amount of insulin permeated after treatment with 0.6, 0.9, 1.2 and 225 
1.5mm MN were found to be 536.35 ± 37.66, 624.27 ± 39.16, 734.28 ±45.27 and 789.20 ± 226 
38.33 µg/cm2 respectively and the respective flux values were 105.59 ± 6.23, 123.6 ± 2.22, 227 
140.67 ± 4.67 and 146.44 ± 3.83 µg/cm²/h. The permeation parameters viz. lag times, 228 
permeability coefficients, diffusion coefficients and insulin content in skin were given in 229 
Table III and the comparative permeation profiles were shown in Fig. 2. 230 
Scaling analyses 231 
It is well known that many parameters of MN, skin and the drug have great influence on the 232 
overall permeation enhancement achieved by this technique8. Using scaling analyses, the 233 
effect of MN length with respect to dimensionless skin thickness (h/L) and dimensionless 234 
surface area of skin (Sa/L2) on the dimensionless amount of insulin permeated (Ct/Cs) were 235 
determined (Fig. 3 (A), (B) respectively). Eqs. 2 & 3 describe such relationships between the 236 
considered dimensionless groups within the given range. 237 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 0.364 �ℎ
𝐿𝐿
�
−0.434
   for 0.8 ≤  ℎ
𝐿𝐿
  ≤ 2.0          ---2 238 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 1.036 �𝑆𝑆𝑎𝑎
𝐿𝐿2
�
−0.217
   for  78.5 ≤ 𝑆𝑆𝑎𝑎
𝐿𝐿2
 ≤ 491.5    ---3 239 
These correlations were determined for given thickness and surface area of skin while the 240 
MN length varies (0.6, 0.9, 1.2 and 1.5 mm). The R2 values for the dimensionless groups 241 
(Ct/Cs vs h/L and Ct/Cs vs Sa/L2) was found to be ≥0.99. 242 
Numerical simulations of permeation experiments 243 
Microphotographs of histological sections can provide an efficient way of predicting the 244 
extent of skin disruption by different MN, which may be used to develop accurate 245 
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simulations of permeation process. The various stages in the treatment of histological images 246 
by MATLAB and COMSOL were shown in Fig. 4. 247 
In order to confirm the validity of the developed simulations, the permeation profiles 248 
obtained from in vitro transdermal permeation experiments and that from simulation (for 0.6 249 
mm MN treatment) were compared (Fig. 5). The similarity factor (f2) for both the profiles 250 
was computed and was found to be 50.4. 251 
 252 
DISCUSSION 253 
A rapid, specific and precise RP-HPLC-PDA method was developed for the quantitative 254 
estimation of insulin and the method was validated according to ICH guidelines. The 255 
validation parameters like specificity, linearity, accuracy, limit of detection, limit of 256 
quantification, precision, robustness, system suitability and stability were all within the 257 
official compendial limits. The developed method was employed for the estimation of insulin 258 
in various samples throughout the experiment. Stability of insulin in saline solution was 259 
determined over a period of 48h at 37ᴼC and showed no significant degradation of insulin till 260 
the end of experimental duration. 261 
AdminPatch® arrays different lengths (0.6, 0.9, 1.2, 1.5 mm) were used to study their effect 262 
on enhancement of insulin skin permeation (Fig. 1). In order to gain insights into the 263 
microconduits formed by the MN application, histological sections (Fig. 4 A) were prepared 264 
and evaluated.  The MN insertions and stratum corneum disruption were clearly evident from 265 
the histological sections. The MN arrays penetrated through the cells without merely 266 
indenting them. Overall, the depth of penetration as measured by ToupView® software was 267 
found to be approximately 40-50% of the needle length and increase in needle length 268 
increased the penetration depth as supported by the microconduits formed by different 269 
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lengths of MNs i.e., 1.2 and 1.5 mm as shown in Fig. 4 A and which may be due to the 270 
resistance shown by skin for MN insertion as a result of its viscoelastic nature (8, 17). 271 
In concurrence with the reports published earlier that a large amount of insulin penetrates 272 
through the skin after the application of high concentrations of insulin at the donor site, the 273 
passive diffusion experiments we conducted resulted in a 1.5 fold increase in the cumulative 274 
amount of insulin permeated by increasing insulin strength from 40IU to 100IU and volume 275 
from 0.5mL to 1mL as donor vehicle (p<0.05) (11, 12). This increase in the insulin 276 
permeation may be attributed to increased chemical potential of insulin in donor 277 
compartment. Based on the above results, 100 IU/mL strength insulin solution at 1 mL donor 278 
volume was used for further MN application studies, the data from which was used for 279 
comparing the relative efficacy of MN of different lengths on enhancement of insulin 280 
permeation and for developing non-dimensional scaling analysis and numerical simulations 281 
of the experiments so as to attain better understanding on the insulin transport behaviour after 282 
MN application. 283 
The permeation parameters of insulin with passive and MN treated studies were compared 284 
(Table III). The results inferred in a 1.18, 1.38, 1.62 and 1.74 fold increase in the cumulative 285 
amount of insulin permeated at the end of 6 h for 0.6, 0.9, 1.2 and 1.5mm MN lengths 286 
respectively when compared to passive permeation results. Similarly a 1.15, 1.34, 1.53, 1.6 287 
fold increase in flux values and 1.15, 1.23, 1.41, 1.9 fold decrease in lag times were observed. 288 
1cm2 circular MN arrays (0.6, 0.9, 1.2 and 1.5 mm) possess 187, 85, 41 and 31 needles with 289 
an effective length of 0.5, 0.8, 1.1 and 1.4 mm, respectively.  The viable epidermis, which is a 290 
cellular, avascular tissue measuring 50-100 μm thickness, poses a significant barrier activity 291 
for transdermal delivery of drugs along with the stratum corneum and that the removal of full 292 
epidermis by calibrated microderm abrasion increased skin permeability of insulin by 11 293 
folds (18).  The ability of longer MNs (1.2 and 1.5 mm) to create microconduits across the 294 
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depth of epidermis without microderm abrasion might explain the increased permeability of 295 
insulin even with relatively less number of pores created in skin. 296 
The concerns of pain and damage to small capillaries in dermis, after application of longer 297 
MNs (1.5mm length) can be over ruled by the previously published data, which states that 298 
MN application (480 to 1450 µm) was significantly less painful to human volunteers (5 to 299 
40% pain scores) when compared to 26-gauge hypodermic needle (19).  Moreover, it was 300 
reported in a previous study that the skin reverted to its normal physiological structure 301 
within 8 h specifically after application of 1.0 mm MN rollers, while the injury by 302 
hypodermic needle still persisted after 24 h in vivo using rat model (10).  The depth of 303 
MN penetrated in to the skin layers we observed was found to be 40-50 % of the MN length, 304 
further strengthens the above statements that nerve damage and pain on MN application are 305 
less probable. 306 
In a previous study, MNs of 800 µm in length loaded with 0.13, 0.25 and 0.44 IU of bovine 307 
insulin, were fabricated from hyaluronic acid resulted in the release of insulin (>90%) within 308 
1 h in both in vitro and in vivo (rat model) permeation studies and that the delivery rate from 309 
insulin loaded MNs was found to be comparable to that obtained with subcutaneous 310 
injection9. Poke and solution application technique employed in our investigation using MN 311 
arrays of 1.2 and 1.5 mm length resulted in 37 and 40 % permeation of insulin loaded dose at 312 
the end of 6 h. Moreover, no saturation or plateau signs in the permeation profile were 313 
observed after MN application (Fig. 2). This can be extrapolated to a continuous and 314 
controlled insulin delivery via the skin under in vivo conditions for more than 6 h. 315 
In corroboration with the data we obtained in this investigation, an in vivo study on rat model 316 
with a similar “poke and solution application” technique, using MN rollers (0.25, 0.5 and 1 317 
mm), was reported by Liu et al., showing a positive relationship between the MN length and 318 
15 
 
hypoglycemic effect produced thereof (10). However, a superior hypoglycemic effect in vivo 319 
may be anticipated with MN arrays application, as the number of MNs piercing the skin per 320 
unit area is more on arrays than on rollers. 321 
Insulin retained within the skin was measured at the end of the experiment in order to have an 322 
idea of insulin retained in skin layers after the permeation studies (Table III). Even though, 323 
there is no correlation of insulin skin content with different experiments, significant amounts 324 
of insulin was distributed in skin layers at the end of the experiments indicating potential skin 325 
deposition of insulin. 326 
The scaling analyses were developed between various dimensionless parameters (Fig. 3 A, B) 327 
in order  to generalise the effect of MN length (L), skin thickness (h) and surface area of skin 328 
(Sa) exposed on the overall amount of insulin permeated (Ct/Cs) (13). Good correlation 329 
(R2≥0.99) was observed between the dimensionless parameters and can be used to predict the 330 
amount of insulin permeated (Ct/Cs) with high accuracy for other MN lengths in the range of 331 
0.6-1.5 mm. 332 
Besides the scaling analyses, a set of well-defined numerical simulations of the permeation 333 
experiments were carried out in order to gain better insights into the effects of MN design, 334 
force of insertion of MN, thickness of skin, etc. in enhancing the insulin permeation, and also 335 
to obtain the information about insulin distribution within the skin during permeation, which 336 
are difficult to obtain directly from the experimental data. In order to carry out simulation 337 
studies of high accuracy, the relative ability of the MNs in creating microconduits in the skin 338 
should be understood precisely. It is well known now that owing to the viscoelastic nature of 339 
skin, the microconduits created do not have the same dimensions as the MN, but may vary 340 
significantly (8, 16), thereby limiting the applicability of MN design parameters to carry out 341 
such simulations.  Microphotographs of histological sections can provide an efficient way of 342 
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predicting the extent of skin disruption by different MNs, which may be used to develop 343 
accurate simulations of the drug(s) permeation process (14).  The numerical simulations 344 
carried out using MATLAB (Fig. 4 B, C) and COMSOL (Fig. 4 D) software, based on in 345 
vitro passive diffusion coefficient values and histological section images (of corresponding 346 
MN geometry) were able to provide information regarding drug distribution within skin at 347 
any time point and depth (14).  348 
The similarity factor (f2) for the in vitro permeation profile and the simulated profile was 349 
found to be 50.4, which indicates that the developed simulations for insulin permeation under 350 
given conditions were in good agreement with the experimental results and therefore can be 351 
used to accurately predict permeation profiles of insulin using histological skin sections 352 
treated specific shape and size of MNs. 353 
Furthermore, these simulation studies can also be used to predict the permeation profiles of 354 
other drugs with different dimensions and designs of MNs using the respective histological 355 
section images and the passive diffusion coefficient of the drug in skin.  These scaling and 356 
simulation studies would help researchers in optimising the MN geometry and other 357 
experimental conditions in further improving the degree of enhancement of insulin or other 358 
drugs. 359 
 360 
CONCLUSION 361 
Transdermal delivery of therapeutic agents like insulin can be of great clinical advantage, as 362 
it is relatively less invasive, provides a continuous delivery with low frequency of 363 
administration and thus increased patient compliance. Our study inferred in a significant 364 
enhancement in insulin permeation across the pig era skin and is donor concentration and 365 
volume dependent. The permeation of insulin after MN application increased with increase in 366 
needle length. The developed scaling correlations and numerical simulations can be of great 367 
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research value for understanding and optimising insulin delivery through transdermal route. 368 
Thus, developing appropriate MN assisted transdermal insulin delivery systems may be a 369 
promising alternative for injectable insulin therapy. However, further in vivo studies are 370 
needed to be carried out to evaluate the therapeutic efficacy of this technique and its 371 
applicability to human use. 372 
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Table I: Model parameters for dimensional analyses of data. 436 
Parameters Value 
Duration for medication (calculation): tm (h) 6 
Surface area of skin exposed for 
permeation: Sa (cm2) 
1.77 
Thickness of stratum corneum: hsc (cm) 0.002 
Total thickness of membrane (distance to 
blood vessel): h (cm) 
0.12 
Effective skin thickness: he (cm) Variable 
Diffusion coefficient in viable skin: Dvs 
(cm2/s) 
Variable 
Volume of receptor compartment 
(distribution): Vd (ml) 
14 
Skin surface/Donor concentration: Cs 
(mg/ml) 
3.5 
MN length: L (cm) Variable 
 437 
  438 
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Table II: Linearity, precision and accuracy data of Insulin 439 
 440 
Linearity (n=3) 
Range 
Regression equation 
Correlation coefficient 
Regression coefficient 
 
5-40 µg/mL 
y =2307x-20464 
R=0.998 
R2=0.996 
Precision (n=6) 
Average peak area of the standard sample (%RSD) 
663000 (1.9) 
Accuracy (n=3) 
% Level of addition 
Mean Percent Recovery (%RSD) 
80 101.3 (0.351) 
100.9 (0.433) 
101.6 (1.028) 
100 
120 
 441 
  442 
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Table III: In vitro transdermal permeation parameters of insulin 443 
Parameter 
Treatment 
Passive 0.6mm MN 0.9 mm MN 1.2 mm MN 1.5mm MN 
Lag time (h) 1.13 ± 0.11 0.98 ± 0.08 0.92 ± 0.1 0.8 ± 0.16 0.59 ± 0.13 
Permeability 
Coefficient  
(cm/h) x10-3 
26.07 ± 1.62 30.16 ± 1.77 35.31 ± 0.63 40.19 ± 1.33 41.83 ± 1.09 
Diffusion 
Coefficient  
(cm2/s) x10-7 
8.938 ± 0.55 10.340 ± 0.60 12.106 ± 0.216 13.779 ± 0.456 14.341 ± 0.37 
Insulin content in 
skin (ng/g) 
651.75 ± 120.94 843.35 ± 139.37 1688.61 ± 291.01 743.2 ± 140.55 565.49 ± 60.69 
 444 
  445 
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FIGURES 446 
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Fig. 1 448 
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LEGENDS TO FIGURES  464 
Fig. 1. Photographs of MN arrays - (A) 0.6 mm; (B) 0.9 mm; (C) 1.2 mm; (D) 1.5 mm 465 
Fig. 2. Mean comparative in vitro skin permeation profiles of insulin  466 
Fig. 3. Scaling relationships for permeation of insulin - (A) General correlation between 467 
dimensionless insulin concentration (Ct/Cs) and dimensionless skin thickness (h/L); (B) 468 
General correlation between dimensionless insulin concentration (Ct/Cs) and dimensionless 469 
surface area (Sa/L2) 470 
Fig. 4. (A) The histological section images of skin; (B&C) Images treated and processed 471 
with MATLAB program (D) Images simulated in COMSOL 472 
Fig. 5. Comparative transdermal permeation profiles of insulin from experimental and 473 
simulation studies 474 
